CNS Oncol. 2018 Dec 14:CNS. doi: 10.2217/cns-2018-0013. [Epub ahead of print]

Cobbs C1, McClay E2, Duic JP3, Nabors LB4, Morgan Murray D5, Kesari S6.

 

Author information:

1. Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Medical Center, Seattle, WA 98122, USA.

2. Melanoma Research Center, California Cancer Associates for Research & Excellence (cCARE), San Marcos, CA 92024, USA.

3. Department of Neuro-oncology, New York University, Winthrop, Mineola, NY 11501, USA.

4. Division of Neuro-oncology, University of Alabama, Birmingham, AL 35294, USA.

5. Nativis, Inc., Seattle, WA 98109, USA.

6. Department of Translational Neuro-Oncology and Neurotherapeutics, John Wayne Cancer Institute & Pacific Neuroscience Institute, Santa Monica, CA 90404, USA.

Abstract

AIM:

 

Evaluation of the Nativis Voyager® device in patients with recurrent glioblastoma (rGBM).

MATERIALS & METHODS:

 

Voyager is a noninvasive, nonthermal, nonionizing and portable investigational device which delivers ultra-low radio frequency energy (ulRFE®) that uses a magnetic field to penetrate tissues to alter specific biologic functions within cells. Patients with rGBM were treated with Voyager alone (V) or Voyager in combination with standard of care (V + SoC). Safety and clinical utility were assessed every 2-4 months.

RESULTS:

 

Data from the first 11 patients treated are reported here. Median progression-free survival was 10 weeks in the V arm and 16 weeks in the V + SoC arm. Median overall survival was 16 months in V arm and 11 months in the V + SoC arm. No serious adverse events associated with the device were reported.

CONCLUSION:

 

These data suggest that the Voyager is safe and feasible for the treatment of rGBM.

PMID: 30547676